Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

Affiliations

• ¹ Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Location VU University Medical Center, Amsterdam, Netherlands. Electronic address: e.vanbommel@amsterdamumc.nl.
• ² Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
• ³ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada.
• ⁴ CardioMetabolism & Respiratory Medicine, Boehringer Ingelheim Canada Ltd./Ltée, Burlington, Ontario, Canada.
• ⁵ Biostatistics & Data Science, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
• ⁶ CardioMetabolism & Respiratory Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany; Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia; Department of Medicine, Würzburg University Clinic, Würzburg, Germany.
• ⁷ Department of Nephrology and Hypertension, University Medical Center, Utrecht, Netherlands.
• ⁸ Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Location VU University Medical Center, Amsterdam, Netherlands.